Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been assigned an average recommendation of "Buy" from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $20.83.

A number of research analysts have commented on the company. Piper Sandler upped their price target on Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research report on Monday, June 2nd. Cantor Fitzgerald initiated coverage on Replimune Group in a research note on Friday, June 20th. They issued an "overweight" rating for the company.

Replimune Group Trading Down 1.4%

REPL traded down $0.13 during midday trading on Wednesday, reaching $9.33. 1,400,154 shares of the company's stock traded hands, compared to its average volume of 859,630. The firm has a fifty day moving average of $9.00 and a two-hundred day moving average of $10.65. The stock has a market capitalization of $719.25 million, a price-to-earnings ratio of -3.04 and a beta of 0.63. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.95 and a quick ratio of 7.95. Replimune Group has a 52 week low of $6.44 and a 52 week high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the company earned ($0.25) earnings per share. On average, equities analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Konstantinos Xynos sold 7,952 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider now owns 146,933 shares of the company's stock, valued at $1,184,279.98. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Sarchi sold 3,749 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $30,179.45. Following the transaction, the insider now directly owns 128,296 shares of the company's stock, valued at approximately $1,032,782.80. This trade represents a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 in the last quarter. 8.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC increased its holdings in shares of Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after purchasing an additional 1,655 shares in the last quarter. US Bancorp DE increased its holdings in shares of Replimune Group by 582.6% in the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after purchasing an additional 3,921 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after purchasing an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd increased its holdings in shares of Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after purchasing an additional 8,183 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Replimune Group by 897.2% in the 1st quarter. GAMMA Investing LLC now owns 8,795 shares of the company's stock worth $902,000 after purchasing an additional 7,913 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.